Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Juste Internacional (JINTER) is a pharmaceutical joint venture established in 2001 between the Spanish private capital group Grupo Juste (specifically Laboratorios Juste) and the Dominican pharmaceutical manufacturer Industria Farmacéutica del Caribe (INFACA). Headquartered in Santo Domingo, Dominican Republic, the company manufactures, commercializes, and distributes a wide range of prescription and over-the-counter medications across the Dominican Republic and Central America. Its product portfolio includes notable brands such as Polibutin AG (trimebutine maleate + dimetilpolisiloxano) for gastrointestinal motility disorders, Viternum (cyproheptadine) for appetite stimulation and allergies, and Balsoprim (sulfamethoxazole + trimethoprim + bromhexine) for respiratory infections. Juste Internacional leverages INFACA's local manufacturing capabilities and a dedicated commercial network to serve healthcare professionals and patients in the region.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Juste Internacional.